Purpose of review Obesity rates worldwide continue to increase and will disproportionately affect older adults because of population aging. This review highlights recent progress pertaining to therapeutic approaches to obesity in older adults.
INTRODUCTION
The population of older adults (!65 years) worldwide currently stands at just under 1 billion and is expected to double within the next 30 years. In Europe today, one in four adults is over the age of 65 years; however, this ratio is anticipated to be one in two by 2050 [1] . Coinciding with the future aging of the population is the ongoing public health epidemic of obesity (BMI ! 30 kg/m 2 ), which has already tripled in prevalence globally within the past 40 years [2] . In the United States, which has the highest population of obese individuals today, 41% of older adults are currently obese and trends suggest the rate will continue to increase [3, 4] .
Obesity is associated with multiple chronic diseases including hypertension, diabetes, heart disease, stroke, and cancer and has been shown to decrease quality of life and life expectancy. For older adults, obesity synergistically exacerbates the agerelated decline in muscle mass and physical function (sarcopenia) causing frailty, an increase in institutionalization rates, and greater healthcare costs [5] . Despite the inevitability of this looming public health issue, there remains a concerning dearth of knowledge regarding the best therapeutic approaches for managing obesity in older persons [6 && ], especially for sarcopenic obese individuals who suffer the worst of both conditions [7] .
The current review summarizes updates from the most recent literature pertaining to both lifestyle and pharmacological interventions for combating obesity in older persons. We also address the latest evidence surrounding the safety of intentional weight loss interventions in the elderly obese population.
CALORIC RESTRICTION
Clinically significant weight loss is not only achievable in the obese older adults, but evidence suggests that increasing age is a strong predictor of adherence to lifestyle interventions in both men and women [8, 9] . In multiple randomized controlled trials (RCTs), caloric restriction ranging from 500 to 1000 kcal/day deficits with or without concurrent exercise training is effective at inducing weight loss [6 && ]. Early evidence also suggests that an intervention with a very low calorie diet (intake of as little as 800 kcal/day) was tolerated in older adults and resulted in 11.1% decrease in body weight over 12 weeks [10 & ]. Caloric restriction alone improves measurable outcomes of physical function and quality of life; however, it has also consistently been shown to decrease lean body mass and bone mineral density (BMD) at the hip assessed by dual-energy X-ray absorptiometry [6 && ]. Although caloric restriction is the first therapeutic option for the treatment of obesity in the general population, there are concerns that this approach may be harmful in older adults because of associated loss of muscle and bone mass, which can further exacerbate sarcopenia and increase fracture risk [11] . The most recent iteration of the American Heart Association/American College of Cardiology/ The Obesity Society guidelines for the management of obesity states 'the overall safety of weight loss interventions for patients aged 65 and older remains controversial' and '. . .there is a need for further research to understand the most appropriate strategies and prescriptions for weight loss for some key populations including older adults' [12] .
These concerns were reinforced in recently published data from the Look AHEAD (Action for Health in Diabetes) trial, which is the first RCT to show an increased risk of frailty fractures with caloric restriction in obese older adults [13 && ]. A significant 39% increase in frailty fractures was noted in the group receiving intensive lifestyle intervention (ILI) compared with the weight-neutral group receiving standard of care after a median follow-up time of 11.3 years. This increase in frailty fractures occurred despite previously documented improvements in physical fitness in the ILI group and highlights the potential risks of weight loss in the older population.
EXERCISE TRAINING
Exercise incorporating aspects of both aerobic endurance training and progressive resistance training does not result in significant weight loss in the absence of caloric restriction, but it does exert positive effects on body composition, improve physical function, increase strength, and positively affect quality of life in aging adults with obesity [6 && ]. A recent study showed that even older adults with class 2þ obesity (BMI ! 35 kg/m 2 ) can safely perform moderate intensity physical activity and benefit in terms of mobility [14 & ]. Although caloric restriction and exercise both individually improve physical function and quality of life, caloric restriction with concurrent exercise training yields better results than either modality alone [15] . Furthermore, the addition of exercise to caloric restriction has been shown to attenuate, though not completely alleviate, loss of muscle mass and BMD.
Recent studies have also focused on the effects of specific exercise modalities -resistance training and aerobic endurance training. An 18-month RCT studying the effect of caloric restriction, caloric restriction and resistance training, or caloric restriction and aerobic endurance training on body composition in 249 obese older adults found that addition of either exercise regimen to caloric restriction resulted in greater loss of total body mass; however, caloric restriction and resistance training preserved fat-free mass more than caloric restriction and aerobic endurance training [16 & ]. These conclusions are supported by data from two separate 5-month RCTs in overweight and obese older adults comparing the effect of caloric restriction and resistance training or caloric restriction and aerobic endurance training on BMD,
KEY POINTS
The foundation of obesity management in older adults is lifestyle intervention incorporating caloric restrictioninduced weight loss with physical activity consisting of aerobic endurance training and progressive resistance training.
Adequate vitamin D and calcium supplementation in addition to a daily protein intake of $1.2 g/kg of body weight is recommended in the setting of lifestyle intervention to maximally preserve muscle mass and bone mineral density during caloric restriction.
Caloric restriction alone is associated with loss of muscle and bone mass which can exacerbate sarcopenia and increase the risk of fractures in obese older adults.
Further investigation is required before recommending other therapies for obesity in older adults such as bariatric surgery, testosterone, and myostatin inhibitors.
suggesting that resistance training attenuates loss of hip BMD during caloric restriction but aerobic endurance training does not [17] . Although these findings suggest that resistance training in particular is crucial in mitigating the negative effects of caloric restriction on fat-free mass, the beneficial effects of aerobic endurance training in the setting of caloric restriction have also been highlighted recently. A 20-week RCT studying cardiorespiratory fitness, fatigue, and disability in 180 obese older men and women undergoing aerobic endurance training alone, with moderate (À250 kcal/day) caloric restriction, or with intensive (À600 kcal/day) caloric restriction found that the addition of moderate or intensive caloric restriction to aerobic endurance training equally improves peak oxygen consumption compared to aerobic endurance training alone [18
We recently reported the results of a 6-month RCT involving 160 obese older men and women with the aim to directly compare the effects of aerobic endurance training, resistance training, or combined training added to matched caloric restriction-induced weight loss (Fig. 1) ]. Physical function assessed by the modified physical performance test improved more in combined training compared to aerobic endurance training or resistance training. Peak oxygen consumption improved equally in aerobic endurance training and combined training, which was greater than the improvement seen in resistance training. Decreases in lean body mass and hip BMD were noted in all intervention groups but was less in resistance training and combined training compared to aerobic endurance training. Muscle strength increased equally in resistance training and combined training, whereas it was only maintained in aerobic endurance training. Dynamic balance assessed by the obstacle course completion time and gait speed improved more in combined training compared to aerobic endurance training or resistance training. These findings indicate additive effects of resistance training and aerobic endurance training on physical function without interference effect from concurrent training in these obese older adults [20, 21] .
The current evidence suggests that obese older adults undertaking caloric restriction should participate in both aerobic endurance training and resistance training, which is consistent with the most recent physical activity recommendations by the American Heart Association and American College of Sports Medicine for overall health in the general population [22] . Local community weight loss programs incorporating exercise can be very successful in this population and significantly improves mobility [23 && ]. We anticipate that these interventions will become increasingly easy to adapt to in community fitness centers and sports clubs as many nations are now adopting more policies to promote healthenhancing physical activity in an effort to combat rising obesity rates [24] .
CALCIUM AND VITAMIN D SUPPLEMENTATION
The American Geriatrics Society currently recommends 1000 IU of vitamin D/day in addition to calcium supplementation in all noninstitutionalized older adults [25] . We agree with this recommendation and emphasize that in obese older adults actively undergoing caloric restriction, supplementation of calcium, up to 1200 mg daily, and vitamin D 3 is crucial to minimize the associated loss of BMD. 
PROTEIN INTAKE
The Institute of Medicine recommended daily allowance (RDA) of protein intake is 0.8 g/kg/day for all adults regardless of age, but many experts and national organizations currently advocate for a daily protein intake of 1.2 g/kg/day or even higher in older adults on the basis of prior evidence suggesting that skeletal muscle in the elderly has a blunted anabolic response to dietary protein [26] . A well designed 6-month RCT in older men with moderate limitations in physical function found no improvement in lean body mass, muscle strength, or physical function when daily protein intake was increased from 0.8 to 1.3 g/kg/day [27 && ]. A 10-week study found that older adults undertaking caloric restriction for obesity saw no improvement in fat-free mass with higher protein intake or with resistance training; however, the combination of both high protein intake and resistance training did lead to improved fat-free mass [28 && ]. These recent trials suggest that the RDA for protein intake of 0.8 g/kg/day is adequate for older adults in most situations, and $1.2 g/ kg/day of protein intake may be beneficial in the setting of caloric restriction and resistance training in obese older adults.
TESTOSTERONE
Both total and free testosterone levels fall with increasing age in men in a pattern that parallels the gradual loss lean mass and increase in adiposity also seen in aging [29] . Comorbidities including obesity are known to accelerate this age-related decline. Based on these observations, testosterone replacement may be a therapeutic option to reverse FIGURE 1. Mean percentage changes in physical function, lean mass, and bone mineral density at the total hip during the interventions. Measures of physical function included the Physical Performance Test (PPT; scores range from 0 to 36, with higher scores indicating better functional status), peak oxygen consumption, Functional Status Questionnaire (FSQ; scores range from 0 to 36, with higher scores indicating better functional status), and strength [measured as total one-repetition maximum (i.e., the total of the maximum weight a participant can lift, in one attempt, in the biceps curl, bench press, seated row, knee extension, knee flexion, and leg press)]. Scores on the PPT were used as an objective measure of frailty (primary outcome), and scores on the FSQ were used as a subjective measure of frailty. The asterisk indicates P < 0.05 for the comparison with the control group, the dagger P < 0.05 for the comparison with the aerobic group, and the double dagger P < 0. Testosterone has recently been shown to protect against loss of lean mass during weight loss in hypogonadal obese middle-aged men (aged 50 years or older) undergoing caloric restriction. A 56-week trial found that testosterone administration during weight loss led to a reduction in loss of lean mass and an increase in fat loss despite similar overall weight loss compared to placebo [32] . Unfortunately, the favorable changes in body composition seen at the conclusion were no longer apparent over a year after discontinuation of testosterone [33 && ]. Although still a promising future therapy, further research is needed to clarify the benefits and risks of testosterone specifically in obese older adults during weight loss therapy.
BARIATRIC SURGERY
A survey suggests that almost 600 000 bariatric surgery procedures were conducted worldwide in 2014 with sleeve gastrectomy (45.9%) and Roux-en-Y gastric bypass (RYGB) (39.6%) being the most popular procedures [34] . Both sleeve gastrectomy and RYGB are effective in older adults at inducing significant weight loss and reducing obesity-associated comorbidities [35] . RYGB appears to be particularly effective at inducing weight loss in older adults compared with sleeve gastrectomy [36 & ]; however, older individuals undergoing RYGB have been noted to have an increased risk of nearly all perioperative complications associated with laparoscopic bariatric surgery and longer hospital stays [37] . Despite these findings, older bariatric patients still have a reduced rate of hospitalization following surgery and no difference in 30-day morality rates [38 & ]. Additional concerns regarding bariatric surgery center around the loss of lean body mass and BMD associated with the profound weight loss following the surgery, which would be particularly detrimental in older adults. In middle-aged adults, one study found minimal loss of lean body mass 5 years after bariatric surgery despite significant overall weight loss [39] . On the other hand, patients undergoing RYGB were noted to have ongoing declines in estimated bone strength at the radius and tibia even after weight stabilization [40] . Furthermore, a retrospective analysis found that RYGB was not only associated with an increased risk of falls and fractures that increased with time, but these risks also had no association with weight lost or calcium and vitamin D supplementation [41 && ]. Given these findings, extreme caution should be exercised before promoting weight loss surgery in older adults until further research can clarify the potential risks and benefits.
MYOSTATIN INHIBITORS
Produced in skeletal muscle and adipose tissue, myostatin (also known as growth and differentiation factor 8) is a part of the transforming growth factor beta superfamily of secreted growth factors which has been shown to act as a negative regulator of muscle growth [42 && ]. Myostatin levels are known to be elevated in atrophied skeletal muscle in both animals and humans. Significant skeletal muscle hypertrophy and hyperplasia has been shown to occur in loss-of-function mutations in myostatin in cases involving humans and a variety of animals including cattle, mice, and dogs. Similar findings were also shown in mouse skeletal muscle overexpressing the myostatin inhibitor follistatin and in cases involving inactivating mutations in the primary myostatin receptor activin receptor IIB [43] . These findings suggest that myostatin inhibition may be a potent therapeutic option in a range of muscle wasting conditions including sarcopenic obesity and muscle loss associated with weight loss.
Significant progress continues to be made in showing the potency of myostatin inhibition in animal models. Recent reports have found that myostatin inhibition increases lean mass and muscle strength in mouse models of muscular dystrophy [44] and Huntington's disease [45] while preventing muscle atrophy and improving physical function poststroke [46] and after anterior cruciate ligament repair [47] . A number of myostatin inhibitors have already progressed to early phase clinical trials and exert their potential effects by blocking the interaction between mature myostatin and its receptors. This is accomplished through use of antibodies, ligand traps, or by overexpressing the natural myostatin inhibitor follistatin [48] .
Thus far, published reports involving intervention studies in humans have been early phase I and II trials in patients with muscular dystrophy [49 & ], sarcopenia [50] , after elective orthopedic surgery [51] , and in healthy individuals [52, 53] . In general, these studies have found the pharmacological intervention to be well tolerated; however, results have been mixed. A study involving a monoclonal antibody targeting myostatin led to increases in appendicular lean mass, decreases in fat mass, and improved gait speed in sarcopenic individuals with a recent history of falls [50] . Others have failed to show improvement over placebo [49 & , 51, 52] .
CONCLUSION
In the older adult population, the prevalence of obesity is anticipated to grow substantially in the coming years because of an increase in the aging population and in the prevalence of obesity itself. Given the public health implications, an effective treatment strategy is essential. We propose that the primary treatment of obesity in older adults should remain centered around lifestyle interventions incorporating caloric restriction and an exercise regimen consisting of both aerobic endurance training and resistance training. Caloric restriction in the absence of exercise training or other measures to attenuate anticipated loss of lean mass and BMD should be avoided. We agree with recommendations to ensure adequate calcium and vitamin D supplementation as well as high-quality protein intake in the setting of caloric restriction. Although therapies such as testosterone and bariatric surgery are already available today, we do not believe that there is sufficient evidence specific to older adults to recommend these options at this time. There may be a potential future role for myostatin inhibitors in the treatment of sarcopenic obesity and muscle loss associated with weight loss, and clinical trials are ongoing.
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